What Is Eliquis (Apixaban)?
Eliquis is the brand name for apixaban, a direct oral anticoagulant (DOAC) that has become one of the most widely prescribed medications in the United States. It belongs to the Factor Xa inhibitor class and is used to reduce the risk of stroke in patients with atrial fibrillation, treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevent clots after hip or knee replacement surgery. For many patients, Eliquis has replaced older anticoagulants like warfarin because it requires no routine blood monitoring and carries a lower risk of serious bleeding in major clinical trials.
Mechanism: How Eliquis Stops Clot Formation
Blood clotting follows a cascade of enzymatic reactions, each activating the next. Factor Xa sits at a critical convergence point in this cascade — it is where the intrinsic (contact activation) and extrinsic (tissue factor) pathways merge, making it a high-value target for anticoagulant drugs. Factor Xa converts prothrombin to thrombin, and thrombin then converts fibrinogen to fibrin — the structural scaffold of a blood clot.
Apixaban is a highly selective, reversible direct inhibitor of Factor Xa. It binds to both free Factor Xa and Factor Xa within the prothrombinase complex (the active clot-forming enzyme assembly). By blocking Factor Xa, apixaban prevents thrombin generation and therefore prevents the formation of new clots, while existing clots can be cleared by the body's natural fibrinolytic system.
FDA-Approved Indications
- Stroke and systemic embolism prevention in adults with non-valvular atrial fibrillation
- Treatment of DVT and PE
- Reduction in recurrent DVT and PE after initial treatment
- Prophylaxis of DVT and PE following hip or knee replacement surgery
The ARISTOTLE Trial: How Eliquis Compares to Warfarin
ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) enrolled 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. Compared to warfarin (target INR 2–3), apixaban reduced stroke or systemic embolism by 21%, reduced all-cause mortality by 11%, and — critically — reduced the rate of major bleeding by 31%. Intracranial hemorrhage (the most feared bleeding complication) was reduced by 58%. These results established apixaban as superior to warfarin across three clinically important outcomes simultaneously: efficacy, safety, and survival.
Eliquis vs. Warfarin: Practical Differences
| Feature | Eliquis (apixaban) | Warfarin |
|---|---|---|
| Mechanism | Direct Factor Xa inhibitor | Vitamin K antagonist (multiple factors) |
| Routine blood monitoring | Not required | Required (INR testing, typically monthly) |
| Food interactions | Minimal | Significant (vitamin K-rich foods affect INR) |
| Drug interactions | CYP3A4 and P-gp inhibitors/inducers | Extensive (many antibiotics, NSAIDs, supplements) |
| Reversal agent | Andexanet alfa (Andexxa) | Vitamin K, FFP, 4-factor PCC |
| Onset of action | Rapid (hours) | Days (requires bridging in urgent situations) |
Reversal Agent: Andexanet Alfa (Andexxa)
One historical limitation of DOACs was the absence of a specific reversal agent for life-threatening bleeding or emergency surgery. Andexanet alfa (brand name Andexxa, developed by Portola/AstraZeneca) was approved by the FDA in 2018 as the first reversal agent for apixaban and rivaroxaban. It works as a decoy Factor Xa molecule — it binds and sequesters apixaban molecules circulating in the bloodstream, rapidly reducing anticoagulant activity. Andexanet alfa is available in many hospital emergency departments and is used when patients on Eliquis experience uncontrolled or life-threatening bleeding.
Key Drug Interactions
Apixaban is metabolized primarily by CYP3A4 and transported by P-glycoprotein (P-gp). Drugs that inhibit both CYP3A4 and P-gp simultaneously can significantly increase apixaban blood levels (increasing bleeding risk), while inducers can reduce apixaban levels (reducing effectiveness):
- Strong inhibitors (increase apixaban exposure): Ketoconazole, itraconazole, ritonavir, clarithromycin
- Strong inducers (decrease apixaban exposure): Rifampin, phenytoin, carbamazepine, St. John's Wort
- Antiplatelet agents and NSAIDs: Aspirin, clopidogrel, and NSAIDs increase bleeding risk when combined with apixaban, though many patients appropriately use low-dose aspirin concurrently under physician guidance
BLEEDING RISK: All anticoagulants increase bleeding risk. Signs of serious bleeding include unusual or excessive bruising, blood in urine (pink or brown urine), red or black tarry stools, coughing or vomiting blood, prolonged bleeding from cuts, and severe headache. Seek emergency care immediately for these symptoms.
PREMATURE DISCONTINUATION: Stopping Eliquis prematurely without medical guidance in patients with atrial fibrillation significantly increases stroke risk. Never stop taking Eliquis without discussing it with your prescriber first.
Want to check how Eliquis interacts with your other medications?
Check Drug InteractionsFrequently Asked Questions
In the ARISTOTLE trial, apixaban demonstrated superior efficacy (less stroke/embolism), superior safety (less major bleeding, significantly less intracranial hemorrhage), and lower mortality compared to well-managed warfarin in atrial fibrillation patients. For most patients with non-valvular AFib, apixaban or another DOAC is now preferred over warfarin by major cardiology guidelines. However, warfarin remains the preferred anticoagulant in specific situations — particularly in patients with mechanical heart valves and in certain stages of kidney disease — where DOACs are not appropriate.
Unlike warfarin, Eliquis does not have significant interactions with vitamin K-rich foods like leafy greens, so patients do not need to restrict their diet. However, grapefruit and grapefruit juice should be consumed cautiously as grapefruit can inhibit CYP3A4. Alcohol in excess increases bleeding risk with all anticoagulants. Patients should discuss any significant dietary changes or herbal supplement use with their healthcare provider, as some supplements (like St. John's Wort) can reduce Eliquis effectiveness.
Yes, in most cases Eliquis needs to be paused before elective surgical procedures to reduce bleeding risk. The timing depends on the type of procedure (high vs. low bleeding risk), the patient's kidney function (which affects how quickly apixaban is cleared), and what the anticoagulation is for. Your surgical team and the prescribing physician should coordinate the peri-procedural anticoagulation management plan. Never stop Eliquis before surgery without medical guidance — abrupt discontinuation in certain patients (particularly those with atrial fibrillation) carries significant stroke risk.